Immunocore (NASDAQ:IMCR – Get Free Report)‘s stock had its “buy” rating restated by research analysts at HC Wainwright in a research report issued on Monday, Benzinga reports. They currently have a $100.00 price objective on the stock. HC Wainwright‘s price objective suggests a potential upside of 220.24% from the stock’s previous close.
Other equities research analysts have also issued reports about the stock. Cantor Fitzgerald reiterated an “overweight” rating on shares of Immunocore in a report on Monday, July 13th. Wall Street Zen cut Immunocore from a “buy” rating to a “hold” rating in a research note on Tuesday, July 28th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a report on Thursday, October 15th. Mizuho boosted their target price on Immunocore from $34.00 to $35.00 and gave the stock a “neutral” rating in a research note on Monday, August 3rd. Finally, Morgan Stanley set a $43.00 price objective on Immunocore in a research note on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $56.38.
View Our Latest Research Report on IMCR
Immunocore Trading Up 0.8%
NASDAQ:IMCR traded up $0.25 during trading hours on Monday, reaching $31.23. 63,139 shares of the stock were exchanged, compared to its average volume of 457,221. Immunocore has a twelve month low of $27.50 and a twelve month high of $40.71. The business has a 50-day moving average of $32.82 and a two-hundred day moving average of $31.66. The company has a market capitalization of $1.61 billion, a price-to-earnings ratio of -84.32 and a beta of 0.81. The company has a quick ratio of 4.44, a current ratio of 4.47 and a debt-to-equity ratio of 0.94.
Immunocore (NASDAQ:IMCR – Get Free Report) last issued its quarterly earnings data on Friday, August 7th. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.01) by ($0.01). Immunocore had a negative net margin of 4.20% and a negative return on equity of 4.54%. On average, equities analysts predict that Immunocore will post 0.04 EPS for the current year.
Hedge Funds Weigh In On Immunocore
Large investors have recently bought and sold shares of the business. Engineers Gate Manager LP boosted its position in shares of Immunocore by 334.3% during the 2nd quarter. Engineers Gate Manager LP now owns 60,327 shares of the company’s stock worth $1,915,000 after acquiring an additional 46,435 shares in the last quarter. Braidwell LP acquired a new stake in shares of Immunocore during the 2nd quarter worth about $16,552,000. Eversept Partners LP purchased a new stake in Immunocore during the first quarter worth approximately $1,183,000. Public Employees Retirement System of Ohio purchased a new stake in Immunocore during the second quarter worth approximately $2,145,000. Finally, Stempoint Capital LP acquired a new position in Immunocore in the first quarter valued at approximately $1,916,000. Hedge funds and other institutional investors own 84.50% of the company’s stock.
Immunocore Company Profile
Immunocore Holdings plc is a biotechnology company that develops T cell receptor (TCR) therapeutics designed to direct the immune system against cancer and other serious diseases. Its proprietary ImmTAC platform uses engineered TCRs to recognize disease-associated peptides presented on the surface of cells and recruit T cells to attack those cells.
The company’s lead product, KIMMTRAK (tebentafusp-tebn), is an ImmTAC therapy approved in the United States and other markets for the treatment of certain adults with unresectable or metastatic uveal melanoma who have a specific HLA-A*02:01 genotype.
Read More
- Five stocks we like better than Immunocore
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
- 5 Beaten-Down Growth Stocks Trading Like Value Plays as Cash Chases Mega-Caps
- Anthropic’s IPO Filing Reveals a Massive Opportunity for AI Infrastructure Giants
- Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Receive News & Ratings for Immunocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunocore and related companies with MarketBeat.com's FREE daily email newsletter.
